Brandy Comyford’s Post

Introducing SynAI: an AI-driven cancer drugs synergism prediction platform. Move beyond the time-intensive and cumbersome traditional methods of drug combination screening. SynAI leverages compound SMILE sequences to rapidly identify potential therapeutic combinations, significantly saving costs and enhancing research efficiency. Download our paper to discover the advantages SynAI brings to your research. ➡️ https://bit.ly/41YI0Le #AI #Cancer #DrugDiscovery #DrugScreening #CancerResearch #Biotech #Bioscience

Effective antibody-drug conjugates (ADCs) hinge on understanding their intricate dynamics. This is where LC-MS/MS shines. Unlike Ligand Binding Assays (LBAs), LC-MS/MS offers unparalleled precision, capturing bound and unbound cytotoxins. Discover how this technique enables precise quantification of ADC components, driving the development of these life-saving therapies. Dive in and learn how we’re enhancing the future of cancer treatment! #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GdmST0

For those of you interested in Knowledge Graphs, you may be interested in hearing about InterVenn’s contributions in the area of glycoscience. One of our glyco-scientists, Dr. Matthew Campbell will be presenting. See link below to register. #glycoproteomics #knowledgegraph #pathwaymapping

Aptamers can bind to a diverse range of targets, making them an alternative to traditional antibodies for a range of research, diagnostic, and therapeutic applications. Optimers® are customized next-generation aptamers that demonstrate significant potential. They possess affinity, specificity, and stability that can be developed towards a broad range of novel and validated biomarkers. In this webinar brought to you by Aptamer Group, David Bunka will discuss the development and use of Optimers for developing cancer treatments and diagnostics. Register now: https://ow.ly/tiLG50RwaKY

Discover the transformative applications of tumor organoid drug screening. Rapidly identify lead agents from compound libraries, quantify drug efficacy across diverse models, and optimize combination strategies for personalized cancer therapy. These advanced methods are setting new standards in drug discovery and patient-specific treatment. Learn how these applications are enhancing drug discovery and personalized cancer treatment. Write to us at info@gvrp.in to know more! GV Research Platform (GVRP) is the authorized distributor of Crown Bioscience services in India. For more information: 🌐 Website: www.gvrp.in .......................... #TumorOrganoids #DrugScreening #OncologyResearch #LibraryScreening #EfficacyQuantification #CombinationTherapy #Bioinformatics #CancerResearch #BiotechInnovation

In cancer #drugdiscovery and development, a number of concerning trends persist: rising costs, increasing complexity, and a growing number of drugs failing to progress beyond #clinicaltrials. Research shows just 1 in 10 investigational #cancer drugs make it past Phase 1 trials, spanning 14 years and costing $2.7 billion on average. Dive into our latest thought leadership piece and explore how #biopharma researchers can leverage the right genomic data to accelerate drug development, delivering better treatments faster. Read the article ➡️ https://lnkd.in/e4ppm5xw

🔬 Recent studies demonstrate the use of microcarriers for large-scale production of HEK293T cells—a challenging task when working with adherent cells. The research focuses on screening active compounds from Fructus evodiae targeting the FGFR4 receptor, which plays a key role in cancer therapy. By utilizing microcarrier technology, the study shows how drug screening can be more efficient and biomimetic, mimicking in vivo conditions for better results. Learn more about this innovative method and its applications on our website 👉: https://lnkd.in/gu6nj7zk Do you need help with large-scale expansion of HEK293T cells? Reach out to our panel of experts to help you adapt to microcarrier culture: info@smartmcs.com.au #HEK293T #CellCulture #Microcarriers #DrugDiscovery #CancerResearch #Biotech #ScalingScience

There are many ways to establish 3D organoid cultures embedded in the tumor microenvironment (TME). Here we illustrate a workflow for establishing a de novo organoid model as a standardized and reproducible model for drug testing, consisting of cancer and non-cancer cell types in the TME. Discover more on our application page linked in the comments below. #cancerresearch #tumormicroenvironment

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

Summary of key XNK achievements in 2023 ▪️Approval of our manufacturing facility and tissue establishment. ▪️Delivery and presentation of preclinical data in our bladder cancer program. ▪️New pipeline project in liver cancer in collaboration with a global pharma. Even though the financial markets are challenging, we are really looking forward to 2024 and are convinced we will deliver great results! #nkcells #atmp #2023